An excess dose of enoxaparin increased risk for death in the non--ST-segment elevation acute coronary syndrome

January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p22
Academic Journal
The article presents a study that investigates the relationship between the enoxaparin dose and risk for in-hospital major bleeding and death of patients with the non-ST-segment elevation acute coronary syndrome (ACS). Cohort analysis has been conducted on the 10,678 patients in the 332 hospitals in the U.S. The study showed that the excess dose of enoxaparin led to a higher incidence of death than did the lower-than-recommended dose.


Related Articles

  • Pharmacoeconomics of Anticoagulants in Acute Coronary Syndrome and Percutaneous Coronary Intervention. Huston, S. A.; Hawkins, D. // Current Pharmaceutical Design;Apr2008, Vol. 14 Issue 12, p1197 

    Economic evaluation plays an important role during almost all stages of pharmaceutical design and use. This paper reviews the recent pharmacoeconomic literature on the use of anticoagulants for acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI). Both ACS and PCI are...

  • Enoxaparin: A Review of its Clinical Potential in the Management of Coronary Artery Disease. Noble, S.; Spencer, C.M. // Drugs;Aug1998, Vol. 56 Issue 2, p259 

    Enoxaparin (enoxaparin sodium) is a low molecular weight heparin (LMWH) that is widely used in the prevention of deep venous thrombosis and pulmonary embolism in patients undergoing orthopaedic or general surgery. Its efficacy in these indications has led to study of its use in patients with...

  • Traditional versus modern anticoagulant strategies: Summary of the literature. Nutescu, Edith; Racine, Eric // American Journal of Health-System Pharmacy;10/15/2002, Vol. 59 Issue 20, pS7 

    Traditional and modern anticoagulant therapies for the management, prophylaxis, and treatment of venous thromboembolism (VTE) and acute coronary syndrome (ACS) and key findings of primary studies are summarized, Significant advances have been made during the past decade in the prevention and...

  • Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions. Joost, Alexander; Kurowski, Volkhard; Radke, Peter W. // Current Pharmaceutical Design;Apr2008, Vol. 14 Issue 12, p1176 

    The administration of heparins (unfractionated or fractionated) represents the current standard as anticoagulant treatment during percutaneous coronary intervention in different clinical settings (elective cases and acute coronary syndrome). Since the incidence of heparin-induced...

  • Factor Xa Inactivation in Acute Coronary Syndrome. Barantke, Melanie; Bonnemeier, Hendrik // Current Pharmaceutical Design;Apr2008, Vol. 14 Issue 12, p1186 

    The increasing incidence of patients who develop acute coronary syndrome (ACS) stresses the importance of effective initial treatment to reduce morbidity and mortality. The recommended initial therapeutic regimen for patients with ACS includes both anticoagulants and antiplatelet agents to...

  • Bivalirudin for Acute Coronary Syndromes. Crawford, Michael H. // Clinical Cardiology Alert;Jan2007, Vol. 26 Issue 1, p1 

    BIVALIRUDIN HAS BEEN SHOWN TO PROVIDE EQUIVALENT outcomes, but less bleeding in patients undergoing elective percutaneous coronary interventions (PCI). The Acute Catheterization and Urgent Intervention Trial Strategy (ACUITY) study was designed to compare heparin plus a glycoprotein (GP)...

  • Bivalirudin for Patients with Acute Coronary Syndromes. Stone, Gregg W.; McLaurin, Brent T.; Cox, David A.; Bertrand, Michel E.; Lincoff, A. Michael; Moses, Jeffrey W.; White, Harvey D.; Pocock, Stuart J.; Ware, James H.; Feit, Frederick; Colombo, Antonio; Aylward, Philip E.; Cequier, Angel R.; Darius, Harald; Desmet, Walter; Ebrahimi, Ramin; Hamon, Martial; Rasmussen, Lars H.; Rupprecht, Hans-J�rgen; Hoekstra, James // New England Journal of Medicine;11/23/2006, Vol. 355 Issue 21, p2203 

    Background: Current guidelines for patients with moderate- or high-risk acute coronary syndromes recommend an early invasive approach with concomitant antithrombotic therapy, including aspirin, clopidogrel, unfractionated or low-molecular-weight heparin, and glycoprotein IIb/IIIa inhibitors. We...

  • Long-Term Anticoagulation in Kawasaki Disease: Initial Use of Low Molecular Weight Heparin is a Viable Option for Patients with Severe Coronary Artery Abnormalities. Manlhiot, Cedric; Brandão, Leonardo R.; Somji, Zeeshanefatema; Chesney, Amy L.; MacDonald, Catherine; Gurofsky, Rebecca C.; Sabharwal, Tarun; Chahal, Nita; McCrindle, Brian W. // Pediatric Cardiology;Aug2010, Vol. 31 Issue 6, p834 

    Patients with severe coronary artery involvement after Kawasaki disease (KD) require long-term systemic anticoagulation. We sought to compare our experience with thrombotic coronary artery occlusions, safety profile, and degree of coronary artery aneurysm regression in KD patients treated with...

  • Bivalirudin decreases hospital costs.  // PharmacoEconomics & Outcomes News;11/29/2008, Issue 567, p10 

    The article discusses a study which shows that the use of bivalirudin reduces hospital costs compared with conventional treatment in patients with moderated and high risk acute coronary syndrome (ACS). It references a study posted on the Web site http://www.themedco.com on November 19, 2008. It...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics